- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
38 result(s) found for: Papillary thyroid carcinoma.
Displaying page 1 of 2.
| EudraCT Number: 2007-002713-39 | Sponsor Protocol Number: Dathyrca 1 | Start Date*: 2007-10-23 | ||||||||||||||||
| Sponsor Name:dept of endocrinology J 106, herlev Hosptial | ||||||||||||||||||
| Full Title: Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer. A double blinded, randomized crossover study. Dathyrca I | ||||||||||||||||||
| Medical condition: in patients with thyroid cancer (follicular or papillary), injektion with recombinant TSH to increase s-TSH before iodine uptake to detect remaining cancer og recurrence of cancer in patients surg... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-004295-19 | Sponsor Protocol Number: 1209-EnTF | Start Date*: 2014-10-08 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||
| Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t... | |||||||||||||||||||||||
| Medical condition: Histologically confirmed differentiated or medullary thyroid cancer by local pathologist. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) IT (Completed) GB (Completed) NL (Completed) DK (Completed) FR (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2010-024133-23 | Sponsor Protocol Number: NO25530 | Start Date*: 2011-10-31 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resista... | |||||||||||||
| Medical condition: Metastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-000422-58 | Sponsor Protocol Number: D4203C00011 | Start Date*: 2013-07-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated T... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Completed) SE (Completed) IT (Completed) ES (Completed) DK (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-001032-12 | Sponsor Protocol Number: PANTHERA | Start Date*: 2008-10-28 | |||||||||||||||||||||
| Sponsor Name:Universitätsklinikum Schleswig-Holstein | |||||||||||||||||||||||
| Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
| Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prohibited by CA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-003668-11 | Sponsor Protocol Number: E7080-G000-604 | Start Date*: 2018-07-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: solid tumors or lymphomas, as defined in parent protocol | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-000144-21 | Sponsor Protocol Number: UCL/10/0299 | Start Date*: 2011-10-05 | |||||||||||||||||||||
| Sponsor Name:University College London | |||||||||||||||||||||||
| Full Title: ION– Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients | |||||||||||||||||||||||
| Medical condition: Patients with differentiated thyroid cancer who are classed as low risk | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-002269-47 | Sponsor Protocol Number: STH18441 | Start Date*: 2015-12-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||
| Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-002419-48 | Sponsor Protocol Number: GETNE-T2216 | Start Date*: 2023-03-27 | |||||||||||||||||||||
| Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||
| Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |||||||||||||||||||||||
| Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-000742-21 | Sponsor Protocol Number: 2017/2527 | Start Date*: 2017-07-31 | |||||||||||||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
| Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with... | |||||||||||||||||||||||
| Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-005933-12 | Sponsor Protocol Number: E7080-G000-201 | Start Date*: 2009-10-29 | |||||||||||
| Sponsor Name:Eisai Limited | |||||||||||||
| Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified... | |||||||||||||
| Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001890-27 | Sponsor Protocol Number: D4200C00079 | Start Date*: 2007-06-15 | |||||||||||
| Sponsor Name:AstraZeneca SAS | |||||||||||||
| Full Title: A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Car... | |||||||||||||
| Medical condition: Advanced or metastatic papillary or follicular Thyroid Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) DK (Completed) SE (Completed) ES (Ongoing) BE (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-005366-17 | Sponsor Protocol Number: 2020/ABM/01/00100 | Start Date*: 2022-09-14 | |||||||||||
| Sponsor Name:Medical University of Bialystok | |||||||||||||
| Full Title: Evaluation of METtformin effect on the fertility of patients treated with 131I for THYRoid cancer – METHYR Study. | |||||||||||||
| Medical condition: Thyroid papilare cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012007-25 | Sponsor Protocol Number: BAY43-9006/14295 | Start Date*: 2009-10-21 | |||||||||||||||||||||
| Sponsor Name:Bayer AG | |||||||||||||||||||||||
| Full Title: A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | |||||||||||||||||||||||
| Medical condition: Differentiated thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) BE (Completed) AT (Completed) SK (Completed) BG (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2014-005199-27 | Sponsor Protocol Number: E7080-G000-211 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Eisai Ltd. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W... | |||||||||||||
| Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003524-32 | Sponsor Protocol Number: NEPHENTE | Start Date*: 2023-01-11 | |||||||||||
| Sponsor Name:Istituti Clinici Scientifici Maugeri SpA Società Benefit | |||||||||||||
| Full Title: Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE) | |||||||||||||
| Medical condition: High-risk thyroid cancers | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005016-21 | Sponsor Protocol Number: FW-2020-1 | Start Date*: 2021-11-15 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Famewave Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Part A- Recurrent and metastatic non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma Part B- Recurrent or metasta... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-016669-27 | Sponsor Protocol Number: P10- | Start Date*: 2010-04-14 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyr... | ||
| Medical condition: Patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of R... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
